Eledon Pharmaceuticals Inc
NASDAQ:ELDN

Watchlist Manager
Eledon Pharmaceuticals Inc Logo
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
Watchlist
Price: 2.21 USD 4.25% Market Closed
Market Cap: 165.8m USD

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
165.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
178.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
84.5B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Eledon Pharmaceuticals Inc
Glance View

Market Cap
165.8m USD
Industry
Biotechnology

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 12 full-time employees. The company went IPO on 2014-09-17. The firm is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. The company is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). The company has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).

ELDN Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top